“Proteomics’ project, entitled ‘Manufacturing the next generation in vitro diagnostic device to predict diabetic kidney disease’, will see the company establish a manufacturing quality control capability for PromarkerD in WA. In doing so, the company hopes the project will support the future large-scale manufacture of the PromarkerD test for both Australia and the South-East Asia region.”
”Ultimately, by enhancing our production capabilities, patients in the region will benefit as they will have easier access to the test,” said Proteomics Managing Director Dr Richard Lipscombe.
Article: Proteomics (ASX:PIQ) awarded $100,000 project grant
